Core Viewpoint - Four Seasons Pharmaceutical (00460) anticipates significant revenue growth, projecting at least 2.5 billion RMB in revenue and 150 million RMB in net profit for the fiscal year ending December 31, 2025, driven primarily by its aesthetic medicine business and innovative drug segment [1] Group 1: Financial Performance - The company expects revenue growth of over 30% compared to the same period last year, with a minimum revenue target of 2.5 billion RMB [1] - Net profit is projected to be no less than 150 million RMB for the same period [1] Group 2: Business Segments - The aesthetic medicine segment is expected to generate over 1.4 billion RMB in revenue and over 700 million RMB in segment profit, with both metrics showing an annual growth rate exceeding 90% [1] - The innovative drug business is entering a harvest phase, significantly improving the company's profit structure [1] Group 3: Financial Health - The company maintains a robust financial position with ample cash reserves [1] - Multiple rounds of share buybacks have been implemented, and the successful spin-off of Xuan Bamboo Biotechnology has optimized the company's financial structure, contributing to profit breakthroughs [1]
港股异动 | 四环医药(00460)盈喜后涨超6% 预期全年收入增速超30% 净利润不低于1.5亿元